Multidisciplinary

NT-proBNP strongly linked to HFpEF risk among early menopausal women

an hour ago

Menopause status does not appear to modify the association between N-terminal pro B-type natriuretic peptide (NT-proBNP), a biomarker of heart failure (HF), and the risk of HF with reduced ejection fraction (HFrEF), according to a study. However, this association is more pronounced among women on their early menopause.

Early remdesivir treatment lowers risk of COVID-19 progression

Jairia Dela Cruz, 17 hours ago

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

Exertional heat injuries surge at dew-point temperature ≥25.1°C

Stephen Padilla, 19 hours ago

Combined data from the Singapore Armed Forces (SAF) and the Meteorological Service Singapore (MSS) show that a dew-point temperature ≥25.1°C on the same day (D) often leads to an increased risk of exertional heat injury (EHI) on the following day (D+1) during military training, reports a study.

Anxiety, depressive symptoms in JIA tied to pain, stress

20 hours ago

Moderate to severe symptoms of anxiety and depression have been reported in about one-fourth of children with juvenile idiopathic arthritis (JIA), according to a study. Such symptoms are associated with pain and stress, but not with other disease manifestations.

Early and consistent: Breakthrough results in HFpEF similar to HFrEF

14 Jan 2022

HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.

Providing Patients with Fast & Effective Relief for Inflamed Sore Throat: An Introduction to the New Flurbiprofen Direct Spray

01 Jan 2022

During the S Pro Symposium sponsored by Reckitt Benckiser, several distinguished speakers shared their insights into the management of sore throat during the COVID-19 era. Topics discussed include therapeutic options for the symptomatic relief of sore throat and the clinical significance of flurbiprofen spray from both local and global perspectives.

The Role of NOAC in Pandemic Era (TREND)

07 Dec 2021

At a Pfizer-sponsored Masterclass, four distinguished speakers shared their insights into the role of NOACs in the management of NVAF and VTE, with a focus on apixaban (Eliquis®, Pfizer). Furthermore, the speakers discussed a stepwise approach to guide treatment choice amid the COVID-19 pandemic.

Diabetes complications and the importance of early diabetes screening

01 Dec 2021

It has been estimated that diabetes – a chronic metabolic disorder resulting in hyperglycaemia – affects 422 million adults globally.1 In 2019, the disease caused 1.5 million deaths worldwide and the number of people with diabetes is expected to reach 642 million by 2040.

Taking the big leapfrog to advance T2D care

01 Dec 2021

During the Guardians for Health Summit 2021 supported by Boehringer Ingelheim, several distinguished speakers shared their insights into the importance of type 2 diabetes (T2D) guideline adherence and patient empowerment, as well as the impact of clinical inertia on the burden of cardiorenal metabolic diseases.

Non-O blood type linked to higher VTE risk in cancer patients

VTE in cancer patients: Does blood type matter?

Pearl Toh, 18 Jan 2022

Non-O blood type appears to be a risk factor for cancer-associated venous thromboembolism (VTE), particularly in patients who have cancer types with low to intermediate thrombotic risk, according to data from the Cancer and Thrombosis Study (CATS) presented at ASH 2021.

Sunshine vitamin, calcium may help avert bone loss associated with AIs

Elvira Manzano, 18 Jan 2022

Supplementation with vitamin D, otherwise called sunshine vitamin, and calcium may help women with breast cancer protect against bone loss associated with aromatase inhibitors (AIs), suggests a 5-year follow-up study from Brazil.

Long-term givosiran use shows sustained clinical benefit in patients with AHP

Elaine Soliven, 15 Jan 2022

Long-term treatment with givosiran showed continued reduction in the composite annualized attack rate (AAR) of porphyria among patients with acute hepatic porphyria (AHP), according to the ENVISION* open-label extension (OLE) study presented at ASH 2021.

Pola-R-CHP triumphs over R-CHOP in improving PFS in DLBCL

Roshini Claire Anthony, 14 Jan 2022

The combination of polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) demonstrated a significant improvement in progression-free survival (PFS) over the standard-of-care (SoC) regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL), according to results of the phase III POLARIX study.

One-time beti-cel gene therapy potentially curative for TDT

Elvira Manzano, 13 Jan 2022

One-time gene therapy in patients with transfusion-dependent β-thalassemia (TDT) results in near-normal or normal haemoglobin levels and transfusion independence, suggesting its curative potential, a long follow-up study has shown.

Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC

Roshini Claire Anthony, 12 Jan 2022

Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.